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in Malaysia due to loss of OmpK36 outer mem-
brane protein coupled with AmpC hyperpro-
duction
Carbapenems are frequently used to treat infections
caused by extended-spectrum b-lactamase (ESBL)-produ-
cing Klebsiella pneumoniae. Resistance to carbapenems in
K. pneumoniae is infrequent and may be due to production
of AmpC cephalosporinase combined with decreased outer
membrane permeability due to loss or alteration of porins.1
A second possible mechanism of resistance is production of
a b-lactamase that is capable of hydrolyzing carbapenems.
This includes the metallo-b-lactamases (MBLs) of class B
and the class A imipenem-hydrolyzing non-MBLs such as
KPC-1.2
In June 2004, an imipenem-resistant strain of K. pneu-
moniae (1/B37) was isolated from the blood culture of an
inpatient at the University of Malaya Medical Centre
(UMMC), Kuala Lumpur, Malaysia. We present a brief clinical
history of the patient and report our findings on the char-
acterization of the mechanism of resistance to imipenem in
the strain.
The patient, a 42-year-old woman who had undergone a
myeloablative allogeneic peripheral blood stem cell trans-
plant for acute myeloid leukemia, presented on day 22 post-
transplant with fever and abdominal pain. Her blood counts
were normal, with hemoglobin of 120 g/dl, white cell count
of 13.2  109/l with 83% neutrophils, and a platelet count of
146  109/l. A working diagnosis of septicemia with likelyacute graft-versus-host disease (GVHD) was made, and rou-
tine blood cultures and blood fungal cultures were carried
out. It was noted at this time that the site of the peripherally
inserted central catheter (PICC), which had been inserted
during the transplant, was inflamed; the catheter was
removed. Empirical treatment with intravenous imipenem,
vancomycin and methylprednisolone was started, and two
days later a triple lumen catheter was inserted. The blood
cultures for bacterial and fungal pathogens were negative.
She developed multiple macular rashes that became progres-
sively worse and the steroid dose was increased. Cyclosporin,
which had been instituted immediately after her transplant,
was then changed to intravenous tacrolimus. Intravenous
immunoglobulin was also given at this time and repeated
fortnightly. On day 28 post-transplant, in view of the
progressive and severe nature of the acute skin GVHD (stage
4), intravenous infliximab 600 mg weekly was instituted.
Earlier skin biopsy findings confirmed the diagnosis of acute
GVHD. Her fever settled and repeated blood cultures showed
no growth; vancomycin was stopped but imipenem was
continued. However, the skin GVHD progressively worsened
and antifungal and antiviral prophylaxis (fluconazole and
acyclovir) were started in view of her severe immunosup-
pressed state. A skin swab taken at this time grew Proteus spp
and Acinetobacter baumannii, and intravenous Unasyn1 was
added. A day later, small skin nodules suggestive of systemic
fungal infection were noted on her back and neck folds.
Fluconazole was stopped and intravenous amphotericin B
was commenced. Following this the patient developed high
fever with new findings in her lungs. Intravenous vancomycin
was added to the antimicrobial regimen. A septic workout
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Figure 1 SDS/PAGE analyses of outer membrane profiles of
Klebsiella pneumoniae isolates. Lane 1: Klebsiella pneumoniae
ATCC 13883. Lane 2: imipenem-susceptible isolate, 64615. Lane
3: imipenem-resistant isolate, 1/B37.was done and Proteus spp, K. pneumoniae and Enterococcus
spp (all sensitive organisms) were isolated from the skin
swab. Blood cultures were carried out on catheter drawn
samples and from a peripherally drawn sample. The labora-
tory reported a possible imipenem-resistant organism that
was sensitive to amikacin, and this was added to her anti-
biotic regime. Unfortunately, the patient continued to dete-
riorate and she died on day 51 post-transplant (day 29 of
admission), the day the blood culture results became avail-
able. Blood cultures taken via the white lumen of the triple
lumen catheter showed a mixed growth of an imipenem-
resistant strain of K. pneumoniae that was also resistant to
the extended-spectrum b-lactams and that appeared to be
only sensitive to amikacin, netilmicin and gentamicin, as well
as an Acinetobacter spp and a Proteus spp. The Proteus spp
was sensitive to cephalosporins (ceftazidime, cefuroxime,
cefotaxime and cefepime), carbapenems (imipenem and
meropenem), aminoglycosides (amikacin, gentamicin and
netilmicin), b-lactam/b-lactamase inhibitor combinations
(amoxicillin—clavulanate and ampicillin—sulbactam) and
ciprofloxacin. The Acinetobacter spp was resistant to
ceftazidime, cefuroxime, cefotaxime, cefepime, imipenem
and meropenem. It was sensitive to amikacin, gentamicin
and netilmicin, ciprofloxacin, cefoperazone—sulbactam and
ampicillin—sulbactam. Blood cultures from the blue lumen
grew amulti-resistant strain of Pseudomonas aeruginosa that
was sensitive to polymyxin B, intermediate to amikacin and
resistant to ceftazidime, cefoperazone, ciprofloxacin, gen-
tamicin, netilmicin, piperacillin, piperacillin—tazobactam,
imipenem and meropenem. Blood cultures (both bacterial
and fungal) taken from the periphery at the same time
showed no growth. Blood for fungal cultures taken about
12 days after admission became positive after the patient’s
death and grew Paecilomyces lilacinus; another blood cul-
ture taken from the periphery on the day before she died
grew Stenotrophomonas maltophilia. The patient had been
on intravenous imipenem for 29 days prior to isolating the
imipenem-resistant strain from the blood culture taken from
the line.
Strain 1/B37 had a minimum inhibitory concentration
(MIC) of 32 mg/ml to imipenem and showed high-level resis-
tance to ceftazidime, cefoxitin, cefuroxime and cefotaxime
with MICs of >256 mg/ml, >256 mg/ml, >512 mg/ml and
256 mg/ml, respectively, while the MIC to cefepime was
4 mg/ml. There was no reduction in the MIC of ceftazidime
in combination with clavulanate confirming negative ESBL
production.
Screening for the presence of AmpC by three-dimensional
test indicated low-level production of AmpC enzymes. The
positive control used was a plasmid-mediated AmpC-produ-
cing K. pneumoniae strain (8551). The cefoxitin agar medium
(CAM)-based assay3 was carried out as an additional test for
the detection of AmpC hyperproduction. The strain was
positive for AmpC enzyme production by a zone of growth
around the periphery of the well.
Screening for MBL production by EDTA-disk synergy test
(EDTA-DST) as described by Lee et al.,4 and for non-MBL
imipenem-hydrolyzing enzymes by the modified Hodge test,3
werenegative. PCR amplification of both theblaIMP gene (F: 5
0-
ACCGCAGCAGAGTCTTTGCC-30; R: 50-ACAACCAGTTTTGCCT-
TACC-30)5 and AmpC gene (F: 50-ATTCGTATGCTGGATCTCGC-
CACC-30; R: 50-CATGACCCAGTTCGCCATATCCTG-30)6 wasnegative. The positive controls used were an IMP-7 producing
strain of P. aeruginosa (Imp699)7 and a K. pneumoniae strain
(8551) that was shown via PCR and DNA sequencing tomediate
the AmpC gene (authors’ unpublished data). Plasmid analyses
showed the presence of three small plasmids of 20 kb, 10 kb
and 5 kb in size. Southern hybridization technique was carried
out on these plasmids using an AmpC probe that was a PCR
product of theAmpCgenegenerated fromthepositivecontrol.
The AmpC probe hybridized to the 20-kb plasmid suggesting
the AmpC gene to be plasmid-mediated.
Crude b-lactamase was prepared by standard sonication
method of the cell pellet and was analyzed by isoelectric
focusing (IEF) on PhastGels using the PhastSystem (Pharma-
cia, Sweden), which showed a single b-lactamase band with a
pI value of 7.6, correlating to SHV-1. Since the AmpC enzymes
were produced in very low amounts, the IEF study could not
detect this enzyme. Furthermore it is difficult to resolve
enzymes with close pI values such as pI 7.6 and pI8.0 (which
correlate to SHV-1 and AmpC, respectively) on PhastGels.
To investigate the likelihood that imipenem resistance
was due to reduced permeability, outer membrane proteins
(OMPs) were extracted. The OMPs were extracted from strain
1/B37 and from an imipenem-susceptible K. pneumoniae
strain, 64615. K. pneumoniae ATCC 13883 that expressed
OmpK35 and OmpK36 porins was used as the positive control.
Porin profiles from all three strains were compared. K.
pneumoniae ATCC 13883 showed the presence of OmpK35
and OmpK36 porins, whereas both porins were absent in
strain 1/B37 (Figure 1), and only OmpK36 porin was present
in strain 64615. Western blot analyses confirmed the absence
of OmpK36 porin in strain 1/B37, while the imipenem-sus-
ceptible K. pneumoniae 64615 strain showed presence of
OmpK36 porin. This suggests that loss of OmpK36 porin
contributed to imipenem resistance.
In this study loss of OmpK35 and loss of OmpK36 porins
were observed. In K. pneumoniae, expression of OmpK35 is
preferentially lost during the development of extended-
spectrum b-lactam resistance, and this is probably due to
its larger pore size compared to OmpK36.8 The additional loss
of OmpK36 would therefore contribute to a wider spectrum
of antibiotic resistance. Cefotaxime, cefoxitin and carbape-
nems penetrate the outer membrane through the OmpK36
porin, thus loss of this porin is known to contribute resistance
to these antibiotics as well.9 The OMP deletion that is the loss
of OmpK36 porin reported in this study is not novel, and the
association between the loss of OmpK36 and increased MICs
of carbapenems has been described in K. pneumoniae produ-
cing a plasmid-mediated AmpC b-lactamase.10
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the isolate was screened for OmpK36 gene using specific
primers (F: 50- AACGTAATAAAGGCATATAAC-30 and R: 50-
CTTCAGCTTGCTTAGAAC-30) that produced a 1167 bp ampli-
con of the complete OmpK36 gene.11 The nucleotide
sequence of this PCR product (accession no.: DQ334272)
was homologous to the DNA sequence of OmpK36 and micF
gene of K. pneumoniae (accession no.: Z33506),12 giving a
99% homology and 98% homology with its deduced amino acid
sequence. Deduced amino acid sequences showed mutations
within the hypervariable domains of OmpK36, which include
insertions of leucine, proline and serine amino acids at
position 186 and substitutions of valine with arginine
(V360R), valine with guanine (V361G) and alanine with glu-
tamine (A362Q), respectively.
Absence of MBLs and imipenem hydrolyzing non-MBLs,
suggests that imipenem resistance in strain 1/B37 was due
to the loss of expression of OmpK36 and AmpC hyperproduc-
tion. AmpC enzymes that were produced at a very low level
may not be sufficient to elevate the imipenem MIC to 32 mg/
ml. However the loss of OmpK36 porin further contributed to
imipenem resistance in this isolate resulting in an increased
MIC of 32 mg/ml. The CAM assay confirmed that the strain was
an AmpC hyperproducer.
In addition, presence of the micF gene, an mRNA inter-
ference complementary gene that interferes with the
expression of the OmpK36 gene,13 further supports the find-
ing of loss of OmpK36 expression. Furthermore impermeabil-
ity-mediated resistance was also contributed by mutational
inactivation due to insertions and substitutions of amino
acids within the hypervariable region of OmpK36;12 unlike
in some findings, loss of porin was due to interruption of porin
genes by insertion sequence.14Acknowledgements
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